Clinical Trial Update: GH21 Combined With D-1553 in KRAS G12C Mutant Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

An early-phase clinical trial evaluating GH21 in combination with D-1553 for locally advanced or metastatic solid tumors harboring a KRAS G12C mutation; the stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors Harboring Kras G12c Mutation

Drugs mentioned

• D-1553
• GH21

Snippet

Sponsor: Suzhou Genhouse Bio Co., Ltd. | Conditions: Locally Advanced or Metastatic Solid Tumors Harboring KRAS G12C Mutation | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING